Imunon Inc（IMNN）資訊與事件IMNNImunon Inc

Imunon Sells Rights to ThermoDox to VoxelDox

Imunon announced that it has entered into an agreement to sell its rights to ThermoDox, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics. Under the agreement, VoxelDox intends to advance the development of ThermoDox for the treatment of glioblastoma multiforme, or GBM, a difficult-to-treat form of brain cancer. In exchange, Imunon will receive an equity ownership stake in VoxelDox, payments of up to $16.5M contingent upon meeting development milestones and significant royalties on future net sales of ThermoDox product following commercial approval. Closing of the transaction is contingent upon VoxelDox completing a planned $2.5M financing to support initiation of a Phase 1 clinical trial in patients with glioblastoma. The companies are announcing the agreement in advance of closing to provide visibility into the intended transaction and Imunon's continued strategic focus. The transaction enables Imunon to retain potential long-term economic participation in ThermoDox while dedicating its financial and operational resources to advancing IMNN-001, the company's lead clinical program. Under the terms of the agreement, upon completion of VoxelDox's financing, Imunon will receive an equity interest of approximately 4.76% in VoxelDox, together with the potential to receive up to $16.5M in aggregate development and sales-based milestone payments and tiered royalties ranging from 3.5% to 6% on net sales of ThermoDox-related products, if approved. IMUNON's realization of any milestone or royalty payments, or of value from its equity position, is subject to VoxelDox's success in financing, developing, and, if applicable, commercializing the asset, and there can be no assurance that any such value will be realized.

Imunon Updates on IMNN-001 Development Program

Imunon is presenting an update on its IMNN-001 development program for women with newly diagnosed advanced ovarian cancer. The program reviews final overall survival results from the randomized Phase 2 OVATION 2 Study, preliminary clinical and translational findings from the Phase 2 minimal residual disease, MRD, study conducted in partnership with Break Through Cancer and led by investigators at The University of Texas MD Anderson Cancer Center, and enrollment and operational progress in the ongoing pivotal Phase 3 OVATION 3 trial. 2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results; Supportive Preliminary MRD Study Data and translational findings; Pathway to confirmatory readout in OVATION 3; Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis

Imunon Continues Phase 2 Study of IMNN-001 with No New Safety Signals

Imunon announced that the Independent Data Monitoring Committee, IDMC, overseeing its ongoing Phase 2 minimal residual disease, MRD, translational study of IMNN-001 has reviewed all safety data to date and recommended that the study continue without modification after identifying no new safety signals and confirming comparable safety across both treatment arms. "The IDMC's recommendation to continue our Phase 2 MRD study without modification provides important independent validation of the favorable safety profile we have consistently observed across our clinical development program," said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON.